Sareum Holdings Plc (SAR Stock) Secured £5 Million Investment

• Sareum has secured £5 Million for autoimmune diseases drugs.
• The SAR stock is trading at £82.6 with a loss of -5.71% during the intraday session.
• Sareum Holdings posts a £3.3 Million loss in the earnings report for the H1-2023 consensus.

Sareum Secured £5 Million for Psoriasis Drug

The Canbridge-based biotechnology company has secured £5 Million for the research & development of its lead candidate SDC -1801. It can be a game-changer therapeutic for autoimmune diseases with an initial focus on psoriasis (a type of skin disease).

That development triggered a slight hike of roughly 10% during an intraday session on 16 August 2023. The SAR stock started a downward trend from there. It indicates a bearish influence in the price action that wrenches the price towards the £83 level. 

The SAR Stock price is currently moving near the annual low of £80 support level, with a bearish trend in the market. If the SAR stock sustains that trend and the price falls further, it might attain a new annual low at £77. 

On the contrary, if the bulls snatch control from bears, the SAR stock might surge. It may retest the 16 August resistance level of £95.0 if the current candle breaks the previous candle high. However, the SAR stock slid -1.58% during the intraday session and is now trading at £81.2 mark.

Sareum Reports a £3.3 Million Loss in H1-2023 Report

Sareum Holdings estimates its post-tax loss for the H1-2023 financial year to be around 3.3 Million. It will be 1.1 Million more than the 2.2 Million loss of the previous year. However, the market predictions are reflecting higher costs expectation and commencing clinical studies. 

Moreover, Sareum Holdings signed agreements with RiverFort Global Opportunities PLC Ltd. That agreement is about an equity prepayment facility of about 5 million. Saerum expects a 2-million deposit in August. This agreement will boost the SAR stock’s value and investors’ confidence in the stock.

Will SAR Attain New Annual Low?

SAR stock witnessed a whopping loss of roughly 42% after achieving an annual high at the 149.0 resistance level. However, the CMF (Chaikin money flow) score is 0.00 during the intraday session,  denoting neither strength nor weakness in the market. The price might stay stuck in consolidation.

The relative strength index (RSI) trades at 30.02 during the intraday session. RSI indicates the heavy participation of sellers in the market. Moreover, DLAR stock price is trading below the 20, 50, 100, and 200-day EMAs. It indicates bearish dominance in the market since 27 June 2023.

Conclusion 

The market structure of Sareum Holdings reflects a downtrend momentum since 5 May 2023. It is the day when the stock touched an annual high. Furthermore, a new development in the autoimmune diseases drug sector may influence the growth. 

Technical Levels 

• Major resistance: £149.0 and £142.0
• Major support: £77.6 and £80.0

Disclaimer

The views and opinions stated by the author, or any people named in this article, are for informational purposes only. They do not establish financial, investment, or other advice. Investing in or trading crypto assets comes with a risk of financial loss.